Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-15-001617
Filing Date
2015-03-13
Accepted
2015-03-12 17:51:12
Documents
11
Period of Report
2015-04-24
Effectiveness Date
2015-03-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A lgnd-def14a_20150424.htm DEF 14A 1730081
2 GRAPHIC g201503121806325374921.jpg GRAPHIC 955
3 GRAPHIC g201503121807151164926.jpg GRAPHIC 466034
4 GRAPHIC g201503121806471944924.jpg GRAPHIC 90795
5 GRAPHIC g201503121806325694923.jpg GRAPHIC 926
6 GRAPHIC g201503121806291624919.jpg GRAPHIC 9775
7 GRAPHIC g201503121807147734925.jpg GRAPHIC 546023
8 GRAPHIC g201503121806325534922.jpg GRAPHIC 934
9 GRAPHIC g201503121807163664928.jpg GRAPHIC 268209
10 GRAPHIC g201503121807158354927.jpg GRAPHIC 553368
11 GRAPHIC g201503121806325224920.jpg GRAPHIC 940
  Complete submission text file 0001564590-15-001617.txt   4402914
Mailing Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037
Business Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 15697029
SIC: 2834 Pharmaceutical Preparations